EP1592386A4 - Composition et methode destinees a traiter les maladies de demyelinisation et la paralysie par administration d'agents de remyelinisation - Google Patents

Composition et methode destinees a traiter les maladies de demyelinisation et la paralysie par administration d'agents de remyelinisation

Info

Publication number
EP1592386A4
EP1592386A4 EP04705266A EP04705266A EP1592386A4 EP 1592386 A4 EP1592386 A4 EP 1592386A4 EP 04705266 A EP04705266 A EP 04705266A EP 04705266 A EP04705266 A EP 04705266A EP 1592386 A4 EP1592386 A4 EP 1592386A4
Authority
EP
European Patent Office
Prior art keywords
paralysis
administration
treatment
composition
demyelinating diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04705266A
Other languages
German (de)
English (en)
Other versions
EP1592386A2 (fr
Inventor
Steve J Karlik
Michael A Pleiss
Andrei W Konradi
Francine S Grant
Christopher M Semko
Daren Dressen
Elizabeth Messersmith
Stephen Freedman
Ted Yednock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Elan Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharmaceuticals LLC filed Critical Elan Pharmaceuticals LLC
Publication of EP1592386A2 publication Critical patent/EP1592386A2/fr
Publication of EP1592386A4 publication Critical patent/EP1592386A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
EP04705266A 2003-01-24 2004-01-26 Composition et methode destinees a traiter les maladies de demyelinisation et la paralysie par administration d'agents de remyelinisation Withdrawn EP1592386A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US44217103P 2003-01-24 2003-01-24
US442171P 2003-01-24
US50031603P 2003-09-05 2003-09-05
US500316P 2003-09-05
PCT/US2004/002028 WO2004066931A2 (fr) 2003-01-24 2004-01-26 Composition et methode destinees a traiter les maladies de demyelinisation et la paralysie par administration d'agents de remyelinisation

Publications (2)

Publication Number Publication Date
EP1592386A2 EP1592386A2 (fr) 2005-11-09
EP1592386A4 true EP1592386A4 (fr) 2007-06-13

Family

ID=32829779

Family Applications (4)

Application Number Title Priority Date Filing Date
EP19152970.0A Withdrawn EP3527228A1 (fr) 2003-01-24 2004-01-26 Composition permettant de traiter des maladies dues à la démyélinisation et à la paralysie par administration d'agents de remyélinisation
EP04705270A Withdrawn EP1592387A4 (fr) 2003-01-24 2004-01-26 Composition permettant de traiter des maladies dues a la demyelinisation et a la paralysie par administration d'agents de remyelinisation
EP04705266A Withdrawn EP1592386A4 (fr) 2003-01-24 2004-01-26 Composition et methode destinees a traiter les maladies de demyelinisation et la paralysie par administration d'agents de remyelinisation
EP11008463A Withdrawn EP2484381A1 (fr) 2003-01-24 2004-01-26 Composition permettant de traiter des maladies dues à la démyélinisation et à la paralysie par administration d'agents de remyélinisation

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP19152970.0A Withdrawn EP3527228A1 (fr) 2003-01-24 2004-01-26 Composition permettant de traiter des maladies dues à la démyélinisation et à la paralysie par administration d'agents de remyélinisation
EP04705270A Withdrawn EP1592387A4 (fr) 2003-01-24 2004-01-26 Composition permettant de traiter des maladies dues a la demyelinisation et a la paralysie par administration d'agents de remyelinisation

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP11008463A Withdrawn EP2484381A1 (fr) 2003-01-24 2004-01-26 Composition permettant de traiter des maladies dues à la démyélinisation et à la paralysie par administration d'agents de remyélinisation

Country Status (16)

Country Link
US (2) US7576101B2 (fr)
EP (4) EP3527228A1 (fr)
JP (4) JP2006516624A (fr)
KR (2) KR20050114212A (fr)
AU (5) AU2004207535A1 (fr)
CA (2) CA2514125A1 (fr)
CO (1) CO5670359A2 (fr)
IL (1) IL169770A (fr)
MX (2) MXPA05007823A (fr)
NO (1) NO20053920L (fr)
PE (1) PE20040942A1 (fr)
RU (1) RU2412721C2 (fr)
SK (1) SK50642005A3 (fr)
TW (2) TW201311238A (fr)
UY (1) UY28170A1 (fr)
WO (2) WO2004066931A2 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
PT1485127E (pt) * 2002-02-25 2011-09-07 Elan Pharm Inc Administração de agentes para o tratamento de inflamação
UY28170A1 (es) 2003-01-24 2004-07-30 Elan Pharm Inc Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
EP1706399A1 (fr) 2004-01-23 2006-10-04 Elan Pharmaceuticals, Inc. Conjugues a base de polyethylene glycol d'acides heterocycloalkyl carboxamido propanoiques
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
US7794700B2 (en) 2004-07-08 2010-09-14 Elan Pharmaceuticals Inc. Multimeric VLA-4 antagonists comprising polymer moieties
CA2478458A1 (fr) * 2004-08-20 2006-02-20 Michael Panzara Traitement de la sclerose en plaques pediatrique
EP1827491A4 (fr) * 2004-11-19 2010-07-14 Biogen Idec Inc Traitement de la sclerose en plaques
US20090169477A1 (en) * 2004-12-03 2009-07-02 Michael Panzara Delaying or preventing onset of multiple sclerosis
DK1874821T3 (da) 2005-04-26 2013-07-08 Trion Pharma Gmbh Kombination af antistoffer med glykokortikoider til behandling af kræft
US7786266B2 (en) * 2005-05-12 2010-08-31 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-DSC2 antibody
BRPI0611285A2 (pt) 2005-05-20 2010-08-31 Elan Pharm Inc derivados de imidazolona fenilalanina
JP2009513783A (ja) * 2005-10-26 2009-04-02 メディバス エルエルシー 芳香族二塩基酸含有ポリ（エステルアミド）ポリマーおよび使用の方法
US20070106035A1 (en) * 2005-10-26 2007-05-10 Medivas, Llc Aromatic di-acid-containing poly (ester amide) polymers and methods of use
US8017612B2 (en) * 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
US9008378B2 (en) 2006-12-20 2015-04-14 The Board Of Trustees Of The Leland Stanford Junior University Arrangement and imaging of biological samples
EP2198040B1 (fr) * 2007-08-31 2018-08-15 Case Western Reserve University Imagerie in vivo de la myéline
US9040715B2 (en) * 2008-09-23 2015-05-26 Georgetown University 1,2-benzisothiazolinone and isoindolinone derivatives
MX2011010971A (es) * 2009-04-17 2012-01-19 Biogen Idec Inc Composiciones y metodos para tratar leucemia mielogena aguda.
US20120258093A1 (en) * 2009-08-20 2012-10-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
SI3202789T1 (sl) 2010-04-16 2020-11-30 Biogen Ma Inc. Protitelesa anti-vla 4
AU2011280039B2 (en) * 2010-06-30 2014-08-07 Victoria Link Ltd Methods and compositions for treatment of multiple sclerosis
WO2012061074A1 (fr) 2010-10-25 2012-05-10 Elan Pharmaceuticals, Inc. Procédés de détermination de différences dans l'activité alpha-4 intégrine par la corrélation de différences des taux de svcam et/ou de smadcam
MX361929B (es) * 2010-11-19 2018-12-19 Eisai R&D Man Co Ltd Star Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes.
AU2012296543B2 (en) 2011-08-16 2016-08-11 Georgetown University Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives
DK3590960T3 (da) 2012-02-29 2023-04-24 Takeda Pharmaceuticals Co Igg-stimuleret remyelinisering af perifere nerver
TWI595007B (zh) 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
KR20210063443A (ko) * 2012-10-09 2021-06-01 바이오젠 엠에이 인코포레이티드 탈수초성 질환의 치료를 위한 복합 요법 및 용도
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
WO2015136472A1 (fr) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anticorps anti-laminine4 spécifiques contre lg4 -5
KR20160127825A (ko) 2014-03-12 2016-11-04 프로테나 바이오사이언시즈 리미티드 항-mcam 항체 및 관련된 사용 방법
KR20170052526A (ko) * 2014-03-13 2017-05-12 프로테나 바이오사이언시즈 리미티드 다발성 경화증에 대한 병용 치료
KR102364840B1 (ko) 2014-11-05 2022-02-18 삼성전자주식회사 신경세포의 탈수초화와 연관된 질환을 치료하기 위한 약학적 조성물 및 그를 이용하는 방법
CN107405331A (zh) * 2014-12-12 2017-11-28 联邦科学和工业研究组织 使用α9整联蛋白拮抗剂从骨髓干细胞龛迁移和释放HSC
US10738121B2 (en) 2015-02-27 2020-08-11 The General Hospital Corporation Therapeutic use of integrin-binding antibodies
CA2981371A1 (fr) 2015-03-10 2016-09-15 The Regents Of The University Of California Inhibiteurs anti-integrine alphavbeta1 et methodes d'utilisation associees
CN106316982B (zh) * 2015-06-30 2020-08-14 中国人民解放军军事医学科学院毒物药物研究所 噻嗪酰胺衍生物及其用途
US10947311B2 (en) * 2015-11-20 2021-03-16 The Board Of Trustees Of The Leland Stanford Junior University VCAM-1 mediated methods and compositions for treating aging-associated impairments
KR20210013623A (ko) * 2018-05-23 2021-02-04 체에스엘 베링 아게 Cidp의 치료
WO2019236417A1 (fr) 2018-06-04 2019-12-12 Biogen Ma Inc. Anticorps anti-vla-4 ayant une fonction effectrice réduite
WO2020092394A1 (fr) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Dérivés d'imidazopyridine utilisés en tant qu'inhibiteurs de l'intégrine alpha4bêta7
CA3115820A1 (fr) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Composes pour l'inhibition de l'integrine .alpha.4.beta.7
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４β７インテグリンの阻害のための化合物
JP7192139B2 (ja) 2018-10-30 2022-12-19 ギリアード サイエンシーズ， インコーポレイテッド α４β７インテグリン阻害剤としてのキノリン誘導体
EP4013499A1 (fr) 2019-08-14 2022-06-22 Gilead Sciences, Inc. Composés pour l'inhibition de l'intégrine alpha 4 bêta 7

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053817A1 (fr) * 1997-05-29 1998-12-03 Merck & Co., Inc. Acide biarylalcanoique utilise en tant qu'inhibiteur de l'adhesion cellulaire
WO1998053814A1 (fr) * 1997-05-29 1998-12-03 Merck & Co., Inc. Composes d'amide heterocycliques utilises en tant qu'inhibiteurs de l'adhesion cellulaire
WO1999006437A1 (fr) * 1997-07-31 1999-02-11 Elan Pharmaceuticals Inc. Composes dipeptidiques sulfonyles inhibiteurs de l'adhesion des leucocytes induite par vla-4
WO2000044408A2 (fr) * 1999-01-29 2000-08-03 Millennium Pharmaceuticals, Inc. Methode de traitement des troubles inflammatoires demyelinisants utilisant des agonistes de la fonction ccr1
WO2001054690A1 (fr) * 2000-01-28 2001-08-02 Biogen, Inc. Compositions pharmaceutiques contenant des composes d'integrine anti-beta 1 et utilisations correspondantes
WO2002002556A2 (fr) * 2000-06-30 2002-01-10 Ortho Mcneil Pharmaceutical, Inc. Derives d'acides amines bicycliques pontes aza utilises comme antagonistes de l'integrine alpha-4
US6489300B1 (en) * 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
US6492421B1 (en) * 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0247091B1 (fr) 1985-11-01 1993-09-29 Xoma Corporation Assemblage modulaire de genes d'anticorps, anticorps ainsi prepares et utilisation
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0279582A3 (fr) 1987-02-17 1989-10-18 Pharming B.V. Séquences d'ADN pour diriger des protéines vers les glandes mammaires afin d'être sécrétées efficacement
EP0330506A3 (fr) 1988-02-26 1990-06-20 Dana Farber Cancer Institute Protéines VLA
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
US5224539A (en) 1991-06-14 1993-07-06 Coen Company, Inc. Cooling system for air heaters and the like
CA2072249C (fr) 1991-06-28 2003-06-17 Saiko Hosokawa Anticorps monoclonal humain liant specifiquement a la surface d'un antigene des membranes des cellules cancereuses
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0672142B1 (fr) 1992-12-04 2001-02-28 Medical Research Council Proteines de liaison multivalentes et multispecifiques, leur fabrication et leur utilisation
DE69419721T2 (de) 1993-01-12 2000-04-27 Biogen, Inc. Rekombinante anti-vla4 antikörpermoleküle
NZ262615A (en) 1993-02-09 1996-02-27 Biogen Inc Treating insulin dependent diabetes (type i) with anti vla4 (very late antigen) antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
JP2001508020A (ja) * 1994-06-02 2001-06-19 シエーリング アクチエンゲゼルシヤフト 多発性硬化症治療用のｐｄｅ ｉｖ阻害剤
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
DE69530392D1 (de) 1994-07-11 2003-05-22 Athena Neurosciences Inc Inhibitoren der leukozytenadhäsion
US6001809A (en) 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
AU3559695A (en) 1994-09-30 1996-04-26 Inex Pharmaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US6284473B1 (en) * 1995-10-02 2001-09-04 Uab Research Foundation P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
US6306384B1 (en) 1996-10-01 2001-10-23 E-L Management Corp. Skin battery cosmetic composition
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
NZ502580A (en) * 1997-07-31 2001-06-29 Elan Pharm Inc 4-amino-phenylalanine compounds which inhibit leukocyte adhesion mediated by VLA-4
US6939855B2 (en) * 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
AR016133A1 (es) * 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
US6291453B1 (en) * 1997-07-31 2001-09-18 Athena Neurosciences, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6559127B1 (en) * 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6362341B1 (en) * 1997-07-31 2002-03-26 Athena Neurosciences, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4
JP2001512134A (ja) 1997-07-31 2001-08-21 エラン・ファーマシューティカルズ・インコーポレーテッド Ｖｌａ−４仲介性白血球付着を阻害する置換フェニルアラニン型化合物
US7030114B1 (en) * 1997-07-31 2006-04-18 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6423688B1 (en) * 1997-07-31 2002-07-23 Athena Neurosciences, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
JP2001512138A (ja) * 1997-07-31 2001-08-21 エラン・ファーマシューティカルズ・インコーポレーテッド Ｖｌａ−４が介在する白血球付着を阻害するベンジル化合物
US6583139B1 (en) * 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6436904B1 (en) * 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
JP2002539080A (ja) * 1999-01-25 2002-11-19 エラン ファーマシューティカルズ，インコーポレイテッド Ｖｌａ−４によって媒介される白血球接着を阻害する化合物
US6387930B1 (en) * 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
ES2415708T3 (es) 1999-12-16 2013-07-26 Biogen Idec Ma Inc. Métodos de tratamiento de la lesión isquémica o hemorrágica del sistema nervioso central mediante el uso de antagonistas anti-integrina alfa4
BR0015875A (pt) * 2000-05-10 2003-06-24 Mayo Foundation Anticorpos igm humano com a capacidade de induzir remielinização, e usos diagnósticos e terapêutico dos mesmos, particularmente no sistema nervoso central
US6653313B2 (en) * 2000-08-10 2003-11-25 Warner-Lambert Company Llc 1,4-dihydropyridine compounds as bradykinin antagonists
US6753135B2 (en) * 2000-09-20 2004-06-22 Surromed, Inc. Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders
PT1485127E (pt) * 2002-02-25 2011-09-07 Elan Pharm Inc Administração de agentes para o tratamento de inflamação
UY28170A1 (es) 2003-01-24 2004-07-30 Elan Pharm Inc Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
US9501219B2 (en) 2012-01-25 2016-11-22 Oracle International Corporation 2D line data cursor

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053817A1 (fr) * 1997-05-29 1998-12-03 Merck & Co., Inc. Acide biarylalcanoique utilise en tant qu'inhibiteur de l'adhesion cellulaire
WO1998053814A1 (fr) * 1997-05-29 1998-12-03 Merck & Co., Inc. Composes d'amide heterocycliques utilises en tant qu'inhibiteurs de l'adhesion cellulaire
WO1999006437A1 (fr) * 1997-07-31 1999-02-11 Elan Pharmaceuticals Inc. Composes dipeptidiques sulfonyles inhibiteurs de l'adhesion des leucocytes induite par vla-4
US6489300B1 (en) * 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
US6492421B1 (en) * 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
WO2000044408A2 (fr) * 1999-01-29 2000-08-03 Millennium Pharmaceuticals, Inc. Methode de traitement des troubles inflammatoires demyelinisants utilisant des agonistes de la fonction ccr1
WO2001054690A1 (fr) * 2000-01-28 2001-08-02 Biogen, Inc. Compositions pharmaceutiques contenant des composes d'integrine anti-beta 1 et utilisations correspondantes
WO2002002556A2 (fr) * 2000-06-30 2002-01-10 Ortho Mcneil Pharmaceutical, Inc. Derives d'acides amines bicycliques pontes aza utilises comme antagonistes de l'integrine alpha-4

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIN L S ET AL: "Specific and dual antagonists of [alpha]4[beta]1 and [alpha]4[beta]7 integrins", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 12, no. 2, 21 January 2002 (2002-01-21), pages 133 - 136, XP002332347, ISSN: 0960-894X *
WEILBACH F X ET AL: "DISEASE MODIFYING TREATMENTS FOR MULTIPLE SCLEROSIS WHAT IS ON THE HORIZON?", CNS DRUGS, ADIS INTERNATIONAL, AUCKLAND, NZ, vol. 11, no. 2, February 1999 (1999-02-01), pages 133 - 157, XP001033418, ISSN: 1172-7047 *

Also Published As

Publication number Publication date
TWI428141B (zh) 2014-03-01
AU2004207535A1 (en) 2004-08-12
NO20053920L (no) 2005-10-24
EP1592387A4 (fr) 2009-05-06
US7576101B2 (en) 2009-08-18
KR20050114212A (ko) 2005-12-05
AU2010212446B2 (en) 2011-03-31
AU2004207536B2 (en) 2010-05-20
EP1592387A2 (fr) 2005-11-09
US20050069541A1 (en) 2005-03-31
EP1592386A2 (fr) 2005-11-09
AU2011201262A1 (en) 2011-04-07
TW200427462A (en) 2004-12-16
KR101260497B1 (ko) 2013-09-12
MXPA05007843A (es) 2005-10-18
JP2011225577A (ja) 2011-11-10
TW201311238A (zh) 2013-03-16
WO2004066931A2 (fr) 2004-08-12
US20050215565A1 (en) 2005-09-29
JP2014040458A (ja) 2014-03-06
MXPA05007823A (es) 2005-10-18
CA2514117A1 (fr) 2004-08-12
CO5670359A2 (es) 2006-08-31
SK50642005A3 (sk) 2006-02-02
UY28170A1 (es) 2004-07-30
AU2010212446A1 (en) 2010-09-09
EP3527228A1 (fr) 2019-08-21
WO2004066932A2 (fr) 2004-08-12
PE20040942A1 (es) 2004-12-28
IL169770A (en) 2012-08-30
WO2004066932A3 (fr) 2006-06-01
NO20053920D0 (no) 2005-08-23
RU2412721C2 (ru) 2011-02-27
CA2514125A1 (fr) 2004-08-12
KR20130100802A (ko) 2013-09-11
JP2006516624A (ja) 2006-07-06
AU2004207536A1 (en) 2004-08-12
JP2007521249A (ja) 2007-08-02
AU2010201472A1 (en) 2010-05-06
WO2004066931A3 (fr) 2005-12-15
EP2484381A1 (fr) 2012-08-08
RU2005126728A (ru) 2006-01-20

Similar Documents

Publication Publication Date Title
EP1592387A4 (fr) Composition permettant de traiter des maladies dues a la demyelinisation et a la paralysie par administration d'agents de remyelinisation
IL180600A0 (en) Compositions and methods of use for treatment of mammalian diseases
TWI340640B (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
WO2005013892A3 (fr) Agents therapeutiques contenant du bore et a resistance hydrolytique et procedes pour les utiliser
EP1631270A4 (fr) Methodes et compositions pour distribuer des butanes catecholiques pour assurer le traitement de pathologies
PT2359856T (pt) Formulação de anticorpos humanos para o tratamento de perturbações associadas ao tnf-alfa
AU2002329990A1 (en) Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
EP1567157A4 (fr) Methodes d'utilisation et compositions recourant a des composes immunomodulatoires pour le traitement et la gestion de syndromes myeloproliferatifs
AU2003210428A1 (en) Phenethanolamine derivatives for treatment of respiratory diseases
ZA200707934B (en) Thereapeutic formulations for the treatment of beta-amyloid related diseases
EP1663104A4 (fr) Compositions therapeutiques a base de porifera destinees au traitement et a la prevention de dermatoses
IL175535A0 (en) Compositions for treatment of neurodegenerative diseases
AU2003268531A8 (en) Materials and methods for treatment of allergic diseases
IL176227A0 (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
EP1560593A4 (fr) Nouvelle composition et procedes pour le traitement de maladies auto-immunes
PL1730144T3 (pl) Podstawione pochodne 1,4,8-triazaspiro[4.5]dekan-2-onu
HK1100812A1 (en) Composition for the prophylaxis/treatment of hbv infections and hbv- mediated diseases
AU2002352533A1 (en) Methods and compositions for treatment of gastric diseases
EP1784173A4 (fr) Composition pharmaceutique destinee a prevenir et a traiter des maladies osseuses metaboliques, contenant des derives d'alpha-arylmethoxyacrylate
AU2002366433A1 (en) Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
EP1709155A4 (fr) Composes et compositions destines au traitement de maladies dysplasiques, et leurs methodes d'utilisation
EP1542664A4 (fr) Methodes et compositions de traitement de troubles maculaires et retinaux
EP1812797A4 (fr) Compositions et methodes permettant de traiter et de prevenir des maladies hyperproliferatives
HK1104800A1 (en) Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
EP1750740A4 (fr) Traitement de maladies et troubles associes aux membranes au moyen de compositions contenant des lantibiotiques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050805

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/21 20060101ALI20051221BHEP

Ipc: A61K 31/185 20060101ALI20051221BHEP

Ipc: A61K 31/16 20060101ALI20051221BHEP

Ipc: A61K 31/10 20060101AFI20051221BHEP

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20070510

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20070504BHEP

Ipc: A61K 31/21 20060101ALI20070504BHEP

Ipc: A61K 31/185 20060101ALI20070504BHEP

Ipc: A61K 31/16 20060101ALI20070504BHEP

Ipc: A61K 31/10 20060101AFI20051221BHEP

17Q First examination report despatched

Effective date: 20071024

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100803